Bristol-Myers Squibb is trading at $65.11, up +10.73% in after-hours trading, but available reports do not confirm the move or identify a verified explanation. - Earlier on October 5, Leerink Partners downgraded the company from Outperform to Market Perform and cut its target from $73 to $59, citing risks around upcoming pipeline results. The news was associated with downward pressure and does not explain the reported gain. - Third-quarter results are expected October 29.